Brought to you by 
Tacurion Pharma receives $15mm in Series A funds concurrent with licensing of nocturia candidate from Astellas
19 Aug 2013
Executive Summary
Tacurion Pharma Inc., the third virtual company formed by Drais Pharmaceuticals Inc. since April 2012, received $15mm in its Series A financing from InterWest Partners, Sutter Hill Ventures, and Astellas Venture Management.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement